David H Ilson, MD, PhD
Cascinu S et al. Tumor response and symptom palliation from RAINBOW, a Phase III trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. Oncologist 2021;26(3):e414-24. Abstract
Kawazoe A et al. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: An open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6(3):209-17. Abstract
Ku G et al. Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2-expressing gastroesophageal adenocarcinoma (GEA). ESMO 2021;Abstract 1380P.
Luo H et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916-25. Abstract
Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. Gastrointestinal Cancers Symposium 2021;Abstract 164.
Reynolds JV et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). ASCO 2021;Abstract 4004.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Zev Wainberg, MD, MSc
Catenacci DV et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). ASCO 2021;Abstract 4010.
Chau I et al. Nivolumab (nivo) plus ipilimumab (ipi) or nivo plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. ASCO 2021;Abstract LBA4001.
Janjigian YY et al. Nivolumab (nivo) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. ESMO 2021;Abstract LBA7.
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384(13):1191-203. Abstract
Kelly RJ et al. Adjuvant nivolumab (nivo) in resected esophageal or gastroesophageal junction cancer (EG/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Shen L et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the Phase III ORIENT-15 study. ESMO 2021;Abstract LBA52.
Sun J-M et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021;398(10302):759-71. Abstract
Van Cutsem E et al. Primary analysis of a Phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. ESMO 2021;Abstract LBA55.
Xu J et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. ESMO 2021;Abstract LBA53.
Xu R-H et al. JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naïve advanced or metastatic esophageal squamous cell carcinoma (ESCC). ESMO 2021;Abstract 1373MO.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival results from a randomized, multicenter, open-label, Phase II study (DESTINY-Gastric01). ASCO 2021;Abstract 4048.